Cystitis, Prostatitis, Urinary Tract Infection
Conditions
Keywords
Men, Cystitis, Urinary Tract Infection, Anti-infective agents, urinary, Fosfomycin
Brief summary
Male urinary tract infections (MUTI) are often less recognised compared to those in women. French clinical guidelines practices recommend the use of antibiotics called fluoroquinolones, which are highly effective in treating MUTIs. However, these antibiotics can lead to rare but serious side effects, such as tendonitis or heart rhythm disturbances. Additionally, fluoroquinolones can contribute to the development of bacterial resistance, making their use inadvisable within six months of treatment. In response to these concerns, we aim to explore a well-established alternative, fosfomycin trometamol (known by the brand name MONURIL®). This antibiotic has a strong track record in treating UTIs in women, with well-documented benefits and minimal associated risks. The primary goal of this study is to assess the effectiveness of fosfomycin trometamol in treating urinary tract infections in men, as well as to evaluate any potential treatment failures.
Interventions
DRUGFosfomycun-trometamol
Study of the efficacy and safety of Fosfomycin trometamol as a 14-day treatment using a 3 g sachet every 2 days for 14 days for the treatment of male urinary tract infections in primary care: open-label, non-randomised, multicentre, inter-regional trial.
Sponsors
University Hospital, Rouen
INSERM UMR1311 DYNAMICURE
Department of General Practice, Rouen University
Health Ministry funding (ReSpiR funds)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men aged 18 years or older. * Consulting in a primary care setting. * Suspected of having a male urinary tract infection (MUTI) by the investigating physician and presenting at least one recent acute symptom (\< 3 months) from the following: * Lower urinary tract symptoms: dysuria, urgency, frequency, hematuria. * Pelvic pain unrelated to urination: suprapubic, perineal, or urethral pain. * Patient has read and understood the information letter and signed the informed consent form. * Affiliation with a social security system or beneficiary of such a system. * No history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or to prevent him/her from giving informed consent
Exclusion criteria
* Presence of one or more criteria for severity of infection * Severe sepsis or septic shock defined by a qSOFA score ≥ 2 * or/and systolic BP less than 100 mmHg: non-inclusion criterion * or/and temperature \< 36°C or \> 38°C * or/and diagnosis of pyelonephritis (pain on lumbar percussion) * or/and presence of abdominal guarding/contraction * or/and presence of a bladder globe above the pubic bone: (suspected acute retention of urine) * or/and known immunosuppression: any immunosuppressive treatment (including corticosteroid therapy \> 10 mg/d for more than 5 days), neutropenia (PNN \< 500/mL) severe malnutrition (albumin \< 30 and/or BMI \< 16), * No diagnosis of male urinary tract infection in the last 3 months, * No ongoing chronic prostatitis, * Known urinary tract abnormality: urinary tract lithiasis, vesico-ureteral reflux, prostate or urinary tract cancer, prostate adenoma treated medically or surgically, urinary tract malformation (including single kidney and urethral stricture). * Acute retention of urine and indication for surgical or interventional drainage * Hyperalgesic form * Urinary tract infection associated with care, on urinary catheter or suprapubic catheter * Urinary tract surgery, cystoscopy, prostate biopsy or urinary catheterisation less than 3 months old * Urinary tract surgery, cystoscopy, prostate biopsy or urinary catheterisation less than 3 months old * Severe disease or high probability of death within 3 months, * Hypersensitivity to fosfomycin trometamol or to any of the excipients (notable excipients: sucrose, dextrose (source of glucose), maltodextrin (source of glucose), orange yellow colouring S (E110)), * End-stage renal disease (creatinine clearance \<10 mL/min), * Patients with glucose and galactose malabsorption syndrome or sucrase/isomaltase deficiency (rare hereditary disease) * Antibiotic taken within 72 hours of diagnosis of male urinary tract infection, * Major cognitive impairment, * Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub- guardianship or curatorship * Any history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or to prevent the subject from giving informed consent. * Known non-adherence to treatment, * Simultaneous participation in another interventional clinical study, * Cannot be taken orally (vomiting)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the efficacy of 14 days of fosfomycin trometamol (FT) treatment for non-febrile male urinary tract infections (MUTIs) in primary care | 14 days | The primary endpoint was defined as the absence of clinical failure up to 14 days after the end of antibiotic treatment. Failure is defined according to SPILF recommendations as : * a change of antibiotic treatment to a reference treatment (see above) for urinary tract infection ; * and/or hospitalisation for urinary tract infection ; * or/and acute retention of urine ; * or/and a new consultation for worsening or persistence of symptoms ; * or/and the appearance of a fever \> 38°C |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Nosological (clinical and biological) description of non-febrile male urinary tract infections (MUTIs) managed in primary care. | 3 months | Improvement in functional urinary symptomatology using a Lickert scale (1. Very unsignificant, 2. Unsignificant , 3. Neither , 4. Significant , 5. Very significant) , 2-5 days 28-35 days and 3 months after the start of treatment with FT; |
| Clinical cure rate 10 to 12 weeks after inclusion (i.e., 8 to 10 weeks after completion of fosfomycin trometamol (FT) treatment) | 8 to 10 weeks after completion of fosfomycin trometamol (FT) treatment | cytobacteriological examination of the urine (CBEU) negative 10 to 12 weeks after the end of treatment ; |
| Microbiological cure rate (assessed by cytobacterial examination of urine), at 14 to 21 days and 10 to 12 weeks after inclusion. | at 14 to 21 days and 10 to 12 weeks after inclusion. | Negative cytobacteriological examination of the urine (CBEU) (leucocyturia \< 10/mm3 OR leucocyturia \> 10/mm3 AND bacteriuria \< 103/mm3 or bacteriuria with a different pathogen) taken 14 to 21 days after the end of antibiotic treatment |
| Establishment of a repository of uropathogens responsible for MUTIs. | 3 months | Regression of urinary signs 10 to 12 weeks after the end of treatment; |
| Analysis of treatment-related adverse effects, 14 days after inclusion | 14 days after inclusion | Adverse events presented by the patient and recorded by the investigating doctor during antibiotic treatment and in the 14 days following the end of treatment. |
Countries
France
Contacts
CONTACTDr SOUDAIS, MD
CONTACTMylene HERVET
PRINCIPAL_INVESTIGATORDr SOUDAIS, MD
University Rouen Hospital
Outcome results
None listed